Compare ATLO & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATLO | SKYE |
|---|---|---|
| Founded | 1903 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 239.2M | 44.9M |
| IPO Year | 2001 | 2013 |
| Metric | ATLO | SKYE |
|---|---|---|
| Price | $27.57 | $0.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 36.4K | ★ 285.3K |
| Earning Date | 04-16-2026 | 03-10-2026 |
| Dividend Yield | ★ 2.90% | N/A |
| EPS Growth | ★ 8.03 | N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $72.66 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.09 | $0.60 |
| 52 Week High | $28.35 | $5.75 |
| Indicator | ATLO | SKYE |
|---|---|---|
| Relative Strength Index (RSI) | 60.11 | 32.30 |
| Support Level | $26.00 | N/A |
| Resistance Level | $28.28 | $0.83 |
| Average True Range (ATR) | 0.65 | 0.05 |
| MACD | 0.05 | -0.00 |
| Stochastic Oscillator | 86.81 | 1.06 |
Ames National Corporation is a bank holding company based in the United States. Through its subsidiaries, it provides a range of banking and other financial products and services to customers in Iowa, mainly in Boone, Clarke, Hancock, Marshall, Polk, Story, Taylor, and Union in central, north-central, and south-central Iowa. The Group offers several financial products and services, including checking and savings accounts, time deposits, commercial, construction, and agricultural loans, personal loans, lines of credit, cash management services, merchant credit card processing, safe deposit boxes, and ATM services, among others. It caters to the banking needs of a diverse range of customers, including individuals, businesses, professionals, and enterprises.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.